Skip to main content
. Author manuscript; available in PMC: 2020 Nov 27.
Published in final edited form as: ACS Nano. 2020 Sep 15;14(10):13268–13278. doi: 10.1021/acsnano.0c05062

Figure 1.

Figure 1.

RGO-PEG nanoplatform for cancer vaccination. (a) Schematic illustration of RGO(CpG)-PEG-neoantigen for LN-targeted delivery of antigens and adjuvants. RGO-PEG nanoplatform coloaded with neoantigen peptides and CpG is administered subcutaneously, leading to efficient delivery to APCs in local LNs, generation of intracellular ROS, and elicitation of robust antitumor T cell immunity. (b, c) AFM images and height analysis (inset) of RGO-PEG. (d) Hydrodynamic size analysis of RGO-PEG and RGO(CpG)-PEG-Adpgk. (e) UV–vis absorption spectrum of GO, RGO-PEG, and RGO(CpG)-PEG-Adpgk. (f) Release profile of Adpgk and CpG from RGO(CpG)-PEG-Adpgk kept in PBS at RT. (g) Raman spectra of RGO-PEG, RGO-PEG incubated with H2O2 (50 mM), and RGO-PEG incubated with human myeloperoxidase (hMPO, 1 mg/mL) + H2O2 (50 mM) at 37 °C for 72 h.